Effect of the third dose of BNT162b2 vaccine in quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare workers
Open accessAbstract
Background: Vaccination is our main strategy to control SARS-CoV-2 infection. Given a decrease in the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers three months following the second BNT162b2 dose, healthcare workers got a third booster dose after six months of completing the original scheme. This study aimed to analyze quantitative SARS-CoV-2 spike 1-2 IgG antibody titers and safety of the third dose. Material and methods: A prospective longitudinal cohort study included healthcare workers who received a third booster dose after six months of the complete BNT162b2 regimen. We assessed the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers 21-28 days after the first and second dose, three months after the complete scheme, 1-7 days following the third dose, and 21-28 days after the boost. Results: The cohort comprised 168 non-immunocompromised participants of 41(10) years old, 67% being women. The third dose was associated with increasing the quantitative antibody titers, regardless of previous SARS-CoV-2 history. In negative SARS-CoV-2 history, the median (IQR) antibody titers increased from 379 (645.4) to 2960 (2010), while in positive SARS-CoV-2 history, from 590 (1262) to 3090 (2080). The third dose had less number of total side effects compared to the other two shots. The most common side effect after the third BNT162b2 shot was pain at the injection site (n=82, 84.5%), followed by tiredness (n=45, 46.4%), with a mild severity (n=36, 37.1%). Tiredness, myalgias, arthralgias, fever, and adenopathy were proportionally higher following the third dose than the two-dose regimen (p<0.05). Conclusion: The third dose applied after six months of the original BNT162b2 regimen provided a good humoral immune response by elevating the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers. The booster dose was well tolerated with no severe side effects after the additional BNT162b2 dose.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Results from clinical trials with over 5,000 people who had received BioNTech/Pfizer booster injections showed that protection conferred by the vaccine was 95.6%.
“However, results from clinical trials with over 5,000 people who had received BioNTech/Pfizer booster injections showed that protection conferred by the vaccine was 95.6%.392–394”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [394]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cuschieri, S. (2019) · Saudi Journal of Anaesthesia · doi:10.4103/sja.sja_543_18 · Cited by 4,331 · cited 1× · see citing works
“This was a prospective observational study that followed the STROBE guidelines [14].”
MethodProtection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114255 · Cited by 1,169 · see citing works
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560 · cited 1× · see citing works
“S/Jannsen, CanSinoBio/Ad5-nCoV), protein subunit (Novavax/NVX-CoV2373, Medicago CoVLP), whole-cell inactivated virus vaccines (Inova/CoronaVac, Sinopharm/ BBIBP-CorV), and DNA vaccines (INO-4800 and ZyCoV-D) [4].”
BackgroundBNT162b2 mRNA COVID-19 Vaccine: First Approval
Lamb, Y. N. (2021) · Drugs · doi:10.1007/s40265-021-01480-7 · Cited by 424 · see citing works
Pellini, R., Venuti, A., Pimpinelli, F., Abril, E., Blandino, G., Campo, F., Conti, L., VIRGILIO, A. D., Marco, F. D., Domenico, E. G. D., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100928 · Cited by 232 · see citing works
Protection against Covid-19 by BNT162b2 Booster across Age Groups
Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L. S., Alroy-Preis, S., Ash, N., Huppert, A., & Milo, R. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2115926 · Cited by 218 · see citing works
Antibody titres decline 3-month post-vaccination with BNT162b2
Favresse, J., Bayart, J., Mullier, F., Elsen, M., Eucher, C., Eeckhoudt, S. V., Roy, T., Wieërs, G., Laurent, C., Dogné, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1953403 · Cited by 155 · see citing works
Bonelli, F., Sarasini, A., Zierold, C., Calleri, M., Bonetti, A., Vismara, C., Blocki, F. A., Pallavicini, L., Chinali, A., Campisi, D., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.01224-20 · Cited by 145 · see citing works
Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials
Chen, M., Yuan, Y., Zhou, Y., Deng, Z., Zhao, J., Feng, F., Zou, H., & Sun, C. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00878-5 · Cited by 141 · see citing works
Fan, Y., Chan, K., & Hung, I. (2021) · Vaccines · doi:10.3390/vaccines9090989 · Cited by 108 · see citing works
Levi, R., Azzolini, E., Pozzi, C., Ubaldi, L., Lagioia, M., Mantovani, A., & Rescigno, M. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149154 · Cited by 105 · see citing works
Peled, Y., Ram, E., Ii Jacob Lavee, I., Segev, A., Matezky, S., Wieder-Finesod, A., Halperin, R., Mandelboim, M., Indenbaum, V., Levy, I., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.08.010 · Cited by 99 · see citing works
Tré‐Hardy, M., Cupaiolo, R., Wilmet, A., Antoine-Moussiaux, T., Vecchia, A. D., Horeanga, A., Papleux, E., Vekemans, M., Beukinga, I., & Blairon, L. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.08.031 · Cited by 69 · see citing works
Sandri, M. T., Azzolini, E., Torri, V., Carloni, S., Pozzi, C., Salvatici, M., Tedeschi, M., Castoldi, M., Mantovani, A., & Rescigno, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-91773-4 · Cited by 48 · see citing works
Pfizer: The miracle vaccine for COVID-19?
Badiani, A. A., Patel, J. A., Ziolkowski, K., et al. (2020) · Public Health in Practice · doi:10.1016/j.puhip.2020.100061 · Cited by 41 · see citing works
Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults
Erice, A., Varillas‐Delgado, D., & Caballero, C. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.08.023 · Cited by 38 · see citing works
Salvagno, G. L., Henry, B. M., Pighi, L., et al. (2021) · Journal of Medical Biochemistry · doi:10.5937/jomb0-33999 · Cited by 27 · see citing works
Evaluation of spike protein antigens for SARS-CoV-2 serology
Jagtap, S., Ratnasri, K., Valloly, P., Sharma, R., Maurya, S., Gaigore, A., Ardhya, C., Biligi, D. S., Desiraju, B. K., Natchu, U. C. M., et al. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114222 · Cited by 18 · see citing works
Levi, R., Ubaldi, L., Pozzi, C., Angelotti, G., Sandri, M. T., Azzolini, E., Salvatici, M., Savevski, V., Mantovani, A., & Rescigno, M. (2021) · Communications Medicine · doi:10.1038/s43856-021-00032-0 · Cited by 13 · see citing works
Salvagno, G. L., Henry, B. M., Pighi, L., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3915349 · Cited by 5 · see citing works
Antibody Titers 3-Months Post-Vaccination with the Pfizer/Biontech Vaccine in GreecePreprint
Κοντοπούλου, Κ., Nakas, C. T., Ntenti, C., Katsioulis, C., Goulas, A., & Papazisis, G. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3899094 · Cited by 3 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [13]Tré-Hardy M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, Della Vecchia A, Horeanga A, et al. Six-month interim analysis of ongoing immunogenicity surveillance of the mRNA-1273 vaccine in healthcare workers: A third dose is expected. Journal of Infection [Internet]. 2021 Aug 23 [cited 2021 Oct 9]; Available from: https://www.sciencedirect.com/science/article/pii/S0163445321004333
Cited by
Sorted by citations
Advances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601 · see citing works
- Authors
- Romero-Ibarguengoitia, M. E., Rivera-Salinas, D., Hernández-Ruíz, Y. G., Armendariz-Vázquez, A. G., González-Cantú, A., Barco-Flores, I. A., González-Facio, R., Montelongo-Cruz, L. P., Del Rio-Parra, G. F., Garza-Herrera, M. R., Leal-Meléndez, J. A., & Sanz-Sánchez, M. Á.
- Affiliations
- University of Monterrey (MX)
- ORCID
- Venue
- PLoS ONE
- Publisher
- openRxiv
- Published
- 2021-10-21
- Volume
- 17
- Issue
- 3
- Pages
- e0263942-e0263942
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8890651
- OpenAlex
- W4214849839
- Cited by
- 29
- References
- 22
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 7 · 2022: 17
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- PLoS ONE (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- healthcare workers, vaccine safety, vaccine adverse events, antibody response, prior SARS-CoV-2 infection, COVID-19 vaccination, injection site pain, fatigue, myalgia, joint pain, fever
- MeSH terms
- COVID-19, BNT162 Vaccine, Adult, Antibodies, Viral, Female, Health Personnel, Humans, Immunoglobulin G, Immunization, Secondary, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
